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a b s t r a c t
Stiff person syndrome (SPS) is a rare autoimmune neurological disorder with antibodies
against antigens involved in neurotransmission of gamma-aminobutyric acid (GABA). About
10% of patients with SPS may develop ataxia. This cerebellar variant is a distinct subset of
SPS with more severe and complex clinical phenotype.
We report the clinical, neuropsychological and neuroradiological ﬁndings in a 39-year-
old female with cerebellar variant of SPS.
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Stiff person syndrome (SPS) is a rare and underdiagnosed
neurological disorder characterized by the muscle rigidity and
superimposed spasms. The rigidity begins insidiously at the
truncal muscles and spreads to the legs. Painful spasms are
precipitated by movement, emotional distress and auditory
startle. Some patients do not show the classic axial distribu-
tion of stiffness. It may start focally from one lower limb,
giving rise to the diagnosis of stiff limb syndrome considered
as a focal form of SPS in which the symptoms are conﬁned to a* Corresponding author at: Department of Neurology, John Paul II Spe
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0028-3843/Published by Elsevier Sp. z o.o. on behalf of Polish Neurololimb, although sometimes this progresses to involve the axial
musculature as well. Antibodies against glutamic acid
decarboxylase (anti-GAD) are diagnostic marker of the SPS,
but they are also described in patients with insulin-depen-
dent diabetes mellitus and in patients with cerebellar ataxia.
Some patients with SPS may develop additional neurologic
abnormalities, including ataxia (10% of patients), epilepsy (5–
10% of patients), abnormal eye movements and mental
disorders (phobias, anxiety, talkativeness, obsessions).
Patients with ataxia (the cerebellar variant of SPS) have more
severe and complex clinical phenotype of SPS with more
prominent stiffness and spasms in the leg and trunk,
cerebellar ataxia; dysarthria; ataxic gait, abnormal eyecialist Hospital, 80 Prądnicka Street, 31-202 Krakow, Poland.
gical Society.
Fig. 1 – MRI of the spine shows an exaggerated lumbar
lordosis.
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suit and gaze-holding nystagmus [1,11].
We report the clinical, neuropsychological and neuroradio-
logical ﬁndings in a 39-year-old female with cerebellar variant
of SPS.
2. Case report
A 39-year-old woman was referred to the department of
neurology with a three-year history of cerebellar ataxia and
progressive muscle rigidity of axial and limb musculature of
unknown origin. In 2008, she began to complain of unsteady
gait, vertigo and diplopia. Neurological examination revealed
nystagmus and broad-based gait.
Six months later, she reported low back pain and stiffness
in the thoracic and lumbar spine with an exaggerated upright
posture. She developed cramps of thoracic and abdominal
muscles and exaggerated lumbar lordosis. The stiffness has
spread to the proximal limb muscles. The spasms of both legs
and the low back were usually precipitated by passive and
voluntary movement, as well as unexpected noise, but at
times occurred spontaneously. Rigidity increased over
months and patient was virtually unable to walk outdoors
without a cane. Over the last several months, her back spasms
had become progressively more painful with exacerbations
during stressful situations resulting in frequent falls and
difﬁculty with standing up. She was afraid to walk even with
an aid. Past medical history did not reveal any neurological or
psychiatric disorder or autoimmune disease. Her family
history was unremarkable. She did not smoke or use illegal
drugs.
On admission, neurological examination revealed sym-
metric paraspinal and lower extremities muscle rigidity, an
exaggerated lumbar lordosis and a prominent thoracic scolio-
sis with vertical nystagmus, cerebellar dysarthria, mild
dysmetria and dysdiadochokinesia of the upper limbs. A
slightly increased tone was noted in her left upper limb, but
muscle strength and range of motion were both normal.
Strength of the lower limbs could not be assessed because of
rigidity and spasms. Sensory examination was normal. Deep
tendon reﬂexes were normal in upper limbs. Knee and ankle
jerks were very brisk bilaterally. Pathological reﬂexes were
absent. The gait was slow and stiff because of the rigidity in her
both legs. She had problems to initiate gait and could not walk
unassisted because she was afraid of falling.
In 2008, neuropsychological study including Rey Auditory
Verbal Learning Test, Clock Drawing Test, Verbal Fluency
Test, Trail Making Test, Stroop Test, Wisconsin Card Sorting
Test, serial number subtractions (7 from 100) revealed
impaired selectivity of attention and executive dysfunction.
When compared with the neuropsychological assessment
completed in 2011 including the same tools, the examination
showed continued impairment of higher-order cognitive
functions and was suggestive of involvement of frontal-
subcortical regions. The assessment revealed increased
executive dysfunction and language problems, impairment
in short-term memory, learning disturbance, decreased
verbal ﬂuency and mental speed, reduced self-criticism,
deﬁcits of attention.Electromyography revealed continuous motor unit activity
in agonist and antagonist muscles at rest. Magnetic resonance
imaging (MRI) of the spine before and after gadolinium
injection showed thoracic scoliosis and hyperlordosis
(Fig. 1). MRI of the brain before and after gadolinium injection
showed no evidence of atrophy of frontal lobes or medial
temporal lobes (Fig. 2).
Single photon emission computed tomography (SPECT)
studies showed bilateral hypoperfusion in frontal lobes,
especially on the right side (Fig. 3). Visual and auditory evoked
potentials were normal. Results of the routine blood biochem-
ical analyses (including complete blood count, serum electro-
lytes, blood urea nitrogen, creatinine, glucose, liver enzymes,
thyroid-stimulating hormone, ceruloplasmin) and urinalysis
were all normal. Anti-GAD autoantibodies were found and
their level was above 20000 IU/mL (normal value <10 IU/mL).
Anti-amphiphysin and paraneoplastic antibodies were not
detected. Gene analysis for spinocerebellar ataxia type 1
(SCA1) found no abnormalities. Paraneoplastic antibodies
were not detected. Analysis of the cerebrospinal ﬂuid (CSF)
wasn't carried out, because the patient refused lumbar
puncture.
The patient was diagnosed with SPS according to currently
accepted clinical criteria [1]. Oral diazepam was administered
at the dose of 30 mg daily and marked reduction of the
stiffness was observed. The patient was able to walk with a
walking stick. After the increase of diazepam to dose 30 mg/
day, levetiracetam at 1000 mg/day was introduced. With this
Fig. 2 – T2-weighted MRI of the brain.
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her gait improved within a few days. Unfortunately, she had
experienced adverse effects (sedation and nausea) and
levetiracetam was discontinued. Currently, she cannot stand
or walk without assistance. At a follow-up visit two months
after her initial presentation, she noticed a moderate decrease
in her stiffness, but loud noises and stressful situations still
induced abrupt muscle spasms, primarily involving her lower
back.
3. Discussion
Cerebellar variant of SPS results in a combined clinical
symptomatology of SPS and cerebellar disease. Symptoms
may start with cerebellar signs followed by muscle spasms and
stiffness or disease begins with stiffness and spasms followedFig. 3 – SPECT showing bilateral hby cerebellar signs or SPS and ataxia may begin concurrently.
In all patients limb ataxia, dysarthria and visual disturbances
are prominent and are more disabling than axial muscle
stiffness [1,11,24].
In patients with stiff person syndrome and concomitant
cerebellar dysfunction increased intrathecal synthesis of anti-
glutamic acid decarboxylase antibodies (anti-GAD) was found
[1,11]. Intrathecal anti-GAD synthesis is suspected of inducing
symptoms in the CNS, presumably by affecting the GABAergic
system. It is suggested that anti-GAD antibodies may also
recognize additional antigenic targets on the inhibitory
cerebellar interneurons resulting in ataxia [24]. As GABAergic
neurons are critical for brainstem control of eye movements,
disruption of GABAergic transmission was proposed as a
pathogenic mechanism of oculomotor disturbances in SPS
resulting in commonly reported by patients diplopia
and blurred vision [3,11,12]. Circulating anti-GAD cause aypoperfusion in frontal lobes.
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neuronal loss. On the basis of the pathogenesis drugs
enhancing GABA transmission like sedative-anxiolytics
(diazepam) and antiepileptic drugs (like levetiracetam) has
been recommended in management of spasm and stiffness in
SPS patients [1,8–10].
A number of associated neuropsychiatric symptoms of SPS
including anxiety and task-speciﬁc phobias have been previ-
ously reported in SPS patients, also a slight decline in cognitive
functioning in relation to premorbid levels was suggested [2].
Isolated cognitive decline in the absence of other neurological
complications may be associated with anti-GAD, presumably
affecting the GABAergic system which is involved in cognitive
function [3]. An isolated cognitive dysfunction with bifrontal
hypoperfusion in SPECT studies may develop in association
with type 1A diabetes and anti-GAD autoimmunity [4].
The issue of a cerebellar contribution to cognitive functions
is still under discussion. The cerebellum projects to the frontal
cortex and loss of cerebellar efferents to the cortex might cause
cognitive impairment. Cerebellar dysfunction may give a
subtype-speciﬁc non-motor symptom described as cerebellar
cognitive affective syndrome which involves mainly language,
executive function and visuospatial skills [5,6].
In 5% of patients, SPS is paraneoplastic and it is associated
with antibodies directed against two other components in the
GABAergic synapse: amphiphysin or gephyrin and usually
occurs in the presence of breast cancer, small cell lung
carcinoma, thymoma and Hodgkin's lymphoma. Such patients
may have more prominent stiffness in the arms and neck [1].
Diagnostic search for other conditions causing stiffness,
cerebellar dysfunction and cognitive impairment did not
reveal any other etiology of those symptoms in our patient.
There was no evidence of associated malignancies or diabetes
mellitus in our patient and she presented slowly progressive
symptoms for more than three years.
In conclusion, SPS and anti-GAD autoimmunity especially
with non-motor symptoms requires further systematic study
to uncover its mechanism in more detail.
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